Kaposiform hemangioendothelioma with Kasabach–Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus

Jamie Cashell, Gayle Smink, Klaus F. Helm, Frederico Xavier

Pediatric Blood & Cancer · 2018 · 29 citations · 13 references

Concepts

Abstract

A full-term newborn with kaposiform hemangioendothelioma (KHE) affecting the right thigh with thrombocytopenia due to Kasabach-Merritt phenomenon (KMP) was referred to our center. After biopsy, he rapidly evolved to severe thrombocytopenia and severe coagulopathy. Standard therapy was initiated with prednisolone and vincristine. His coagulopathy worsened to life-threatening hemorrhage necessitating aggressive blood products replacement. Sirolimus was added; he became transfusion independent with no further bleeding and reduction in tumor size. Addition of sirolimus to treatment of vascular anomalies with hemostatic complications should be considered as part of early treatment for patients with KMP/KHE.

References

13